Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis

Completed · Not applicable

Conditions studied: Amyotrophic Lateral Sclerosis (ALS)

In brief

This post-approval study will follow 60 participants who have ALS, documented chronic hypoventilation, and bilateral phrenic nerve function, and who undergo the surgical implantation procedure to receive the NeuRx Diaphragm Pacing System device. Participants who are successfully implanted with the device will use it for daily diaphragm conditioning sessions. Participants will be followed for at least two years (until the last enrolled participant reaches the 2-year follow-up visit). Safety and probable benefit outcome measures will be assessed.

Key facts

Study ID

NCT01605006

Run by

Synapse Biomedical

People needed

97

Starts

2012-07-01

Expected to finish

2017-02-01

Last updated by the study team

2020-03-27

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 21 or older.
• Participants with familial or sporadic ALS diagnosed as laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria.
• Bilateral phrenic nerve function clinically acceptable as demonstrated by bilateral diaphragm movement with fluoroscopic sniff test or with EMG recordings and nerve conduction times.
• Chronic hypoventilation was documented by at least one of the following:
• FVC less than 50% predicted, or
• \|MIP\| less than 60 cmH2O, or
• PaCO2 greater than or equal to 45 mmHg, or
• Nocturnal SaO2 less than or equal to 88% for at least five continuous minutes
• Suitable surgical candidate.
• Negative pregnancy test in female participants of childbearing potential.
• Informed consent from patient or designated representative.

You may not qualify if…

• Underlying cardiac or pulmonary disease that would increase the risk of general anesthesia.
• Underlying pulmonary diseases that were present prior to ALS that would affect pulmonary tests independent of ALS.
• Uncontrolled excessive secretions.
• FVC less than 45% predicted at time of surgery.
• Preexisting implanted electrical device such as pacemaker or cardiac defibrillator.
• Pre-existing diaphragm abnormality such as a hiatal hernia or paraesophageal hernia of abdominal contents going into the thoracic cavity.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States
• California Pacific Medical Center -- Forbes Norris MDA/ALS Research Center — San Francisco, California, United States
• University of Colorado Denver — Denver, Colorado, United States
• Mayo Clinic — Jacksonville, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• Stony Brook University — Stony Brook, New York, United States
• Duke University — Durham, North Carolina, United States
• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• Providence St. Vincent Medical Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.